Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker CDXS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Raymond De Vre Director | CDXS Codexis, Inc. | Sale | 1,088 | $1.11 | $1,208 Sale | Form 4 ↗ |
| Jun 11, 2026 | Raymond De Vre Director | CDXS Codexis, Inc. | Sale | 2,605 | $2.37 | $6,174 Sale | Form 4 ↗ |
| Feb 24, 2026 | Stefan Lutz Chief Scientific Officer | CDXS Codexis, Inc. | Sale | 5,862 | $1.13 | $6,624 Sale | Form 4 ↗ |
| Feb 6, 2026 | Stefan Lutz Chief Scientific Officer | CDXS Codexis, Inc. | Sale | 2,492 | $1.31 | $3,265 Sale | Form 4 ↗ |
| Feb 6, 2026 | Georgia Erbez See Remarks | CDXS Codexis, Inc. | Sale | 3,826 | $1.31 | $5,012 Sale | Form 4 ↗ |
| Feb 6, 2026 | Alison Moore President and CEO, Director | CDXS Codexis, Inc. | Sale | 3,826 | $1.31 | $5,012 Sale | Form 4 ↗ |
| Jan 7, 2026 | Stefan Lutz CSO | CDXS Codexis, Inc. | Sale | 4,685 | $1.70 | $7,965 Sale | Form 4 ↗ |
| Dec 1, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 8,533 | $1.67 | $14.3K Sale | Form 4/A ↗ |
| Dec 1, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 245,000 | $1.67 | $409.1K Sale | Form 4/A ↗ |
| Nov 28, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 2,490 | $1.75 | $4,358 Sale | Form 4/A ↗ |
| Nov 28, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 105,000 | $1.75 | $183.8K Sale | Form 4/A ↗ |
| Nov 26, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 5,000 | $1.74 | $8,700 Sale | Form 4/A ↗ |
| Nov 26, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 148,318 | $1.74 | $258.1K Sale | Form 4/A ↗ |
| Nov 21, 2025 | Dennis P. Wolf Director | CDXS Codexis, Inc. | Sale | 8,952 | $1.56 | $14.0K Sale | Form 4 ↗ |
| Nov 12, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 165,000 | $1.96 | $323.4K Sale | Form 4 ↗ |
| Nov 12, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 27,459 | $1.94 | $53.3K Sale | Form 4 ↗ |
| Nov 12, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 890,000 | $1.94 | $1.7M Sale | Form 4 ↗ |
| Nov 11, 2025 | Raymond De Vre Director | CDXS Codexis, Inc. | Sale | 1,413 | $1.74 | $2,459 Sale | Form 4 ↗ |
| Nov 11, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 13,211 | $1.80 | $23.8K Sale | Form 4/A ↗ |
| Nov 11, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 535,000 | $1.80 | $963.0K Sale | Form 4/A ↗ |
| Nov 10, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 3,318 | $1.73 | $5,740 Sale | Form 4/A ↗ |
| Nov 10, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 205,000 | $1.73 | $354.6K Sale | Form 4/A ↗ |
| Nov 7, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 10,000 | $1.70 | $17.0K Sale | Form 4/A ↗ |
| Nov 7, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Sale | 296,682 | $1.70 | $504.4K Sale | Form 4/A ↗ |
| Oct 13, 2025 | Alison Moore Chief Technical Officer | CDXS Codexis, Inc. | Sale | 6,239 | $2.51 | $15.7K Sale | Form 4 ↗ |
| Oct 13, 2025 | Georgia Erbez Chief Financial Officer | CDXS Codexis, Inc. | Sale | 6,239 | $2.51 | $15.7K Sale | Form 4 ↗ |
| Aug 4, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 780 | $2.84 | $2,215 Buy | Form 4 ↗ |
| Jul 31, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 84,220 | $2.68 | $225.7K Buy | Form 4 ↗ |
| Jul 30, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 1,578 | $2.80 | $4,418 Buy | Form 4 ↗ |
| Jul 29, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 8,422 | $2.82 | $23.8K Buy | Form 4 ↗ |
| Jul 18, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 100,000 | $2.82 | $282.0K Buy | Form 4 ↗ |
| Jun 27, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 100,000 | $2.39 | $239.0K Buy | Form 4 ↗ |
| Jun 16, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 50,898 | $2.24 | $114.0K Buy | Form 4 ↗ |
| Jun 13, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 99,102 | $2.23 | $221.0K Buy | Form 4 ↗ |
| Jun 12, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 100,000 | $2.25 | $225.0K Buy | Form 4 ↗ |
| May 28, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 5,000 | $2.36 | $11.8K Buy | Form 4 ↗ |
| May 23, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 2.32M | $2.36 | $5.5M Buy | Form 4 ↗ |
| May 1, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 20,000 | $2.32 | $46.4K Buy | Form 4 ↗ |
| Apr 30, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 25,000 | $2.31 | $57.8K Buy | Form 4 ↗ |
| Apr 25, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 25,000 | $2.24 | $56.0K Buy | Form 4 ↗ |
| Apr 17, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 45,000 | $2.09 | $94.0K Buy | Form 4 ↗ |
| Apr 16, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 70,000 | $2.13 | $149.1K Buy | Form 4 ↗ |
| Apr 15, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 25,000 | $2.23 | $55.8K Buy | Form 4 ↗ |
| Apr 8, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 100,000 | $1.98 | $198.0K Buy | Form 4 ↗ |
| Apr 3, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 75,000 | $2.30 | $172.5K Buy | Form 4 ↗ |
| Apr 2, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 5,000 | $2.46 | $12.3K Buy | Form 4 ↗ |
| Apr 1, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 35,000 | $2.48 | $86.8K Buy | Form 4 ↗ |
| Mar 21, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 92,923 | $2.54 | $236.0K Buy | Form 4 ↗ |
| Mar 20, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 7 | $2.54 | $17.98 Buy | Form 4 ↗ |
| Mar 13, 2025 | Opaleye Management Inc. 10% owner | CDXS Codexis, Inc. | Buy | 85,000 | $2.54 | $215.9K Buy | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:41 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances